What they were paid
Immunovant Director Compensation Table · all 2 fiscal years held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2026 | $64,348 | $397,754 | $392,824 | $0 | $854,926 |
| FY2025 | — | — | — | $0 | — |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Immunovant, Inc. DEF 14A filed July 22, 2026, accession 0001764013-26-000092, and prior-year filings. Open the filing on EDGAR.
How this board is paid
company policy · FY2026Immunovant pays directors a $50,000 cash retainer and $425,000 in 75% RSU / 25% Option.
Committees
FY2026 · as the proxy prints themAudit · Compensation
The rest of the Immunovant board
FY2026 · as the company reported each| Director | Role | FY2026 total |
|---|---|---|
| Andrew Fromkin | Independent Director | $397,351 |
| Atul Pande, M.D | Independent Director | $384,850 |
| Douglas Hughes | Independent Director | $392,117 |
| Eric Venker, M.D., Pharm.D | Director | — |
| Frank M. Torti, M.D | Chair of the Board | $4,094,228 |
| Jacob Bauer | Independent Director | $862,075 |
The full Immunovant compensation record
free company briefThis page is one director within Immunovant's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat